NCT02634853已完成3 期
A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 429
- 试验地点
- 1
- 主要终点
- Corneal Fluorescein Staining
研究概览
简要总结
The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be at least 18 years of age Provided written informed consent Have a reported history of dry eye Have a history of use or desire to use eye drops for dry eye
排除标准
- •Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months Have any planned ocular and/or lid surgeries over the study period Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1 Have an uncontrolled systemic disease Be a woman who is pregnant, nursing or planning a pregnancy Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study Have a known allergy and/or sensitivity to the test article or its components Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1 Be unable or unwilling to follow instructions, including participation in all study assessments and visits
研究组 & 干预措施
Tavilermide Ophthalmic Solution
Active Comparator
1% Tavilermide Ophthalmic Solution
干预措施: 1% Tavilermide Ophthalmic Solution (Drug)
Vehicle Ophthalmic Solution
Placebo Comparator
Placebo Ophthalmic Solution
干预措施: Placebo Ophthalmic Solution (Drug)
结局指标
主要结局
Corneal Fluorescein Staining
时间窗: Day 57
Ocular Discomfort
时间窗: Day 57
次要结局
- Corneal Fluorescein Staining(Day 15)
- Ocular Dryness(8 weeks)
- Ocular Surface Disease Index(Day 57)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye DiseaseKeratoconjunctivitis SiccaNCT02665234Mimetogen Pharmaceuticals USA, Inc.400
已完成
3 期
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry EyeDry Eye SyndromesDry Eye DiseaseKerato Conjunctivitis SiccaNCT05848128Mimetogen Pharmaceuticals USA, Inc.642
已完成
Unknown
To test the safety of hydration mist on eyes during usage.CTRI/2023/05/053058DPKA Universal Consumer Ventures Private Limited33
已完成
2 期
Safety and Efficacy of an Ophthalmic Solution in Dry Eye DiseaseDry Eye DiseaseNCT00758784Bausch & Lomb Incorporated38
已完成
3 期
Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS PlusCataractNCT00333268Alcon Research369